ID
17447
Description
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 3/Visit 3.
Keywords
Versions (3)
- 9/14/16 9/14/16 -
- 10/2/16 10/2/16 -
- 12/14/16 12/14/16 -
Uploaded on
September 14, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
- StudyEvent: ODM
Description
Vital Signs
Description
Weight
Data type
float
Measurement units
- kg
Description
Blood pressure and heart rate will be measured once, after the subject sits quietly for at least 5 minutes.
Data type
integer
Description
Blood pressure
Data type
integer
Measurement units
- mmHg
Description
Heart Rate
Data type
integer
Measurement units
- bpm
Description
Concomitant Medications (See Description)
Description
Adverse Events (See Description)
Description
Physical Examination (See Description)
Description
Pedal Oedema (See Description)
Description
End of visit reminder (See Description)
Similar models
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
- StudyEvent: ODM